Spero Therapeutics to Present at Investor Conferences in March

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. BABA
7. AVGO
8. SPCX
9. BJ
10. NTES

Get Alerts SPRO Hot Sheet

Price: $1.22 +0.83%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present at the following investor conferences in March 2021:

The Cowen 41st Annual Healthcare ConferencePanel Name: Respiratory and Infections PanelPanel Presentation Date and Time: Monday, March 1st at 10:20 – 11:20 AM EST

Oppenheimer 31st Annual Healthcare ConferenceCorporate Presentation Date and Time: Tuesday, March 16th at 10:00 – 10:30 AM EST

Webcasts of corporate presentations may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab. Replays of corporate presentations will be archived on the website for 90 days following the conclusion of each event.

About Spero TherapeuticsSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Spero Investor and Media Contact:Sharon KlahreVice President, Investor Relations857-242-1547[email protected]